当前位置: 首页 >> 检索结果
521. Everolimus in heavily pretreated metastatic breast cancer: Is real world experience different?
Drugs targeting mammalian target of rapamycin signaling pathway have been recently approved for treatment of hormone receptor (HR) positive metastatic breast cancer (MBC). However, there is lack of real world data from India on the use of this therapeutic strategy.
522. Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India.
Heavily pretreated metastatic breast cancer (MBC) remains a major therapeutic challenge with limited treatment options this. Eribulin, an anti-microtubule agent, has been recently approved for this indication. There are sparse data from the Asian region for eribulin and merits exploration.
523. Spectrum of cancer in adolescents and young adult: An epidemiological and clinicopathological evaluation.
Changing scenario of cancer in adolescents and young adult (AYA) age group becomes an emerging and alarming problem. The age span that falls under the AYA umbrella, i.e., 15-29 years, is broad and having unique characteristic as compared to older and pediatric cohort. Only a few data are available in English literature about this age group where the spectrum of cancer varies accordingly as the function of age.
524. Efficacy and safety analysis of rituximab combined with chemotherapy in the treatment of B-cell lymphoma patients complicated with hepatitis B virus infection.
Lymphoma combined with hepatitis B infection occupies a relatively higher incidence in China than that of in Europe and America.
525. Cancer and cure: A critical analysis.
Cancer is one of the most dreaded diseases of the 20th century and spreading further with continuance and increasing incidence in the 21st century. The situation is so alarming that every fourth person is having a lifetime risk of cancer. India registers more than 11 lakh new cases of cancer every year, whereas, this figure is above 14 million worldwide. Is cancer curable? The short answer to this question is "Yes." In fact, all cancers are curable if they are caught early enough. Cancer cells continue to grow unless one of four things occur: (1) The cancerous mass is removed surgically; (2) using chemotherapy or another type of cancer-specific medication, such as hormonal therapy; (3) using radiation therapy; or (4) the cancer cells shrink and disappear on their own.
526. Incidence of prostate cancer at a single tertiary care center in North Karnataka.
作者: S C Ghagane.;R B Nerli.;M B Hiremath.;A T Wagh.;P V Magdum.
来源: Indian J Cancer. 2016年53卷3期429-431页
Prostate cancer (PC) remains one of the most common cancers affecting men today. Thus, understanding the prevalence, disease characteristics, and changing demographics of Indian PC patients has emerged as an important aspect of study.
527. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
作者: A Joshi.;A Ramaswamy.;V Noronha.;V M Patil.;A Chandrasekharan.;A Goel.;A Sahu.;N Sable.;A Agrawal.;S Menon.;K Prabhash.
来源: Indian J Cancer. 2016年53卷3期423-428页
Sorafenib is an established upfront treatment option for metastatic RCC (mRCC). There is no published literature regarding its performance in Indian Patients. We present an analysis of Sorafenib use in our institute and attempt to validate the Heng criteria as a prognostic score in these patients.
528. The longest tumor diameter in one dimension as a predictor for skeletal metastasis in renal cell carcinoma.
作者: And Dwivedi.;A Srinivasan.;S Kumar.;S Trivedi.;V K Shukla.;R C Shukla.
来源: Indian J Cancer. 2016年53卷3期420-422页
Renal cell carcinoma (RCC) comprises a diverse group of malignant neoplasms that have multifarious histopathological features and biological behavior. One-third of RCC patients develops skeletal metastasis with a poor 5-year survival rate. Data explaining how some of these tumors show sooner bony metastasis than expected is sparse. The objective of this study was to identify whether tumor size can act as a predictor of bony metastases among patients of RCC.
529. Pattern of care in operable endometrial cancer treated at a rural-based tertiary care cancer center.
作者: S B Dessai.;D Adrash.;M Geetha.;S Arvind.;J Bipin.;S Nayanar.;K Sachin.;M S Biji.;S Balasubramanian.
来源: Indian J Cancer. 2016年53卷3期416-419页
An audit was planned to study the demographics, staging, treatment details, and outcomes of operable endometrial cancers.
530. A cohort study of vulvar cancer over a period of 10 years and review of literature.
The objective of this study was to study the risk factors, management protocols, and the outcome of vulvar cancer cases over a period of 10 years in a tertiary care hospital.
531. Does magnetic resonance imaging accurately predict residual disease after unplanned excision of soft-tissue sarcomas?
Often, it is difficult to assess the presence of residual disease after an unplanned excision in soft-tissue sarcomas. Inadequate excision leads to disease recurrence and inferior oncological outcomes while unnecessary excision may lead to additional surgical procedures with inherent morbidity and increased cost of treatment. There is a paucity of literature comparing the preoperative imaging findings with the final histopathology report to accurately assess the presence of residual disease.
532. Accelerated versus conventional radiation fractionation in early stage carcinoma larynx.
In our study, we have treated cases of early glottic carcinoma by two different dose-fractionation schedules in relation to overall treatment time.
533. Squamous cell carcinoma of the oral cavity and oropharynx in young adults.
Head and neck squamous cell carcinoma (SCC) is a disease of older age group predominately in the sixth and eighth decades of life. The incidence of oral SCC (young age <40 years) varies between 0.4% and 3.9%. There has been increasing trend in younger age group worldwide as well as in India as reported by many studies.
534. Pediatric head and neck squamous cell carcinoma: A retrospective observational study.
Pediatric head and neck squamous cell carcinoma is very rare. Limited data are available in English literature on this issue due to paucity of cases. Hence, we retrieved data of pediatric head and neck cancer in younger age group (≤20 years of age) for evaluation of clinicopathological characteristics, treatment, and outcome of this emerging issue.
535. Skin involvement and ipsilateral nodal metastasis as a predictor of contralateral nodal metastasis in buccal mucosa cancers.
作者: M Mair.;S Nair.;S K Thiagarajan.;J Agrawal.;D Nair.;P Chaturvedi.
来源: Indian J Cancer. 2016年53卷3期394-396页
In view of low incidence of contralateral nodal metastasis and increase in the morbidity, the opposite neck is not routinely addressed. However, contralateral nodal metastasis is seen frequently in a certain group of patients. Identifying those factors associated with higher chances of contralateral nodal metastasis may help in optimizing the treatment.
536. Induction chemotherapy with cisplatin and ifosfamide in locally advanced inoperable squamous cell carcinoma of the head and neck: A single-institution experience.
Induction chemotherapy (ICT) in patients with head and neck cancer has been studied since a long time. The addition of taxanes to the cisplatin and 5-fluorouracil (5FU) (PF) regimen results in superior antitumor activity. We did this study to see the response and toxicity of ICT with cisplatin and ifosfamide followed by concurrent chemoradiotherapy (CRT) in locally advanced, unresectable squamous cell carcinoma of head and neck (SCCHN).
537. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India.
作者: P Ramteke.;V Seenu.;R Prashad.;S D Gupta.;V Iyer.;Svs Deo.;A Gogia.;S Mathur.
来源: Indian J Cancer. 2016年53卷3期366-371页
Use of neoadjuvant chemotherapy (NACT) in locally advanced breast cancer (LABC) enables tumor reduction and conservative surgery. It is proposed in some studies that there may be an alteration in the hormonal receptor (HR) status and human epidermal growth factor receptor 2 (Her-2)/neu immune-expression following NACT.
538. The pattern of invasive lobular carcinoma in the patients diagnosed with breast cancer from Balochistan.
作者: A H Baloch.;A N Khosa.;N Bangulzai.;H Sadia.;M Ahmed.;F Khan.;M Jan.;M Tareen.;M H Kakar.;J Shuja.;H K Naseeb.;J Ahmad.
来源: Indian J Cancer. 2016年53卷3期363-365页
Invasive lobular carcinoma (ILC) is the second most common type of breast cancer accounting for 5%-15% of all the breast cancer cases. The present study was performed on 171 breast cancer patients from Balochistan registered in CENAR (Center for Nuclear Medicine and Radiotherapy), Quetta.
539. Incidence and pattern of bone metastases at presentation in Indian carcinoma breast patients.
Breast cancer (BC) is the most common female cancer and frequently metastases to the bones. Breast cancer among Indian women occurs a decade earlier and more aggressive than the western population. Screening guidelines are based on western studies. The aim of our study is to assess the role of Technitium99m bone scan (TBS) in screening Indian EBC patients at presentation. We also looked at the pattern of BM in all stages of BC.
540. Epidemiological and survival analysis of triple-negative breast cancer cases in a retrospective multicenter study.
作者: R Sarin.;L Khandrika.;Rnm Hanitha.;A Avula.;M Batra.;S Kaul.;H Raj.;S Shivkumar.;S Gupta.;E Khan.;Tps Bhandari.;Svss Prasad.;V A Reddy.;G Swarnalata.;M Bakre.;S Chatterjee.;J Jain.
来源: Indian J Cancer. 2016年53卷3期353-359页
This is a retrospective study with data collected from breast cancer cases from five major Apollo Hospitals across India, as part of a biobanking process. One aspect of our study focused specifically on data from triple-negative breast cancer (TNBC) cases. The aim of this study was to analyze epidemiology, treatment options, and survival of the patients with TNBC. Our goal was to draw conclusions on the preponderance of the disease and also to understand the outcomes using the existing therapy options.
|